Olive Capital
VC Fund
San Francisco, United States
Olive Capital (OC) is an early-stage investment firm focused on the tech and synthetic biology sectors. Our portfolio includes diverse companies in these spaces, including Pardes (NASDAQ: PRDS), Akasa, Science, Substack, Ender, Orchid Health, and Rewind. OC builds on the experience of founding partner Olivia Wang, who previously headed up the USoffice of ZhenFund, managing an AUM of $2 billion and a portfolio of 40+ companies. The combination of our vast VC network and strong founder relationships grants us access to highly competitive investment rounds, to the extent that we are often the sole small fund alongside institutional heavyweights. We take firm evaluation and selection very seriously, pairing in-house research with the expertise of external domain advisors and institutional partners. OC Fund I launched in 2021, and OC Fund II is currently in the pipeline.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Olive Capital invests in
Stages Olive Capital invests in
Countries Olive Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $3M–$11M
- Series A
- $13M–$25M
Investment Focus
Industry
- Health Care 6 (32%)
- Biotechnology 5 (26%)
- Artificial Intelligence 3 (16%)
- Medical 2 (11%)
- Software 2 (11%)
Stage
- Seed 16 (84%)
- Series A 2 (11%)
- Pre-Seed 1 (5%)
Country
- United States 13 (68%)
- Hong Kong 1 (5%)
- Singapore 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Olivia Wang
Founder and Managing Member
|
Founder and Managing Member | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Standard Fleet
|
Software for electric vehicle owners | $13M / Series A / Sep 10, 2025 | |
Neon Health
|
Neon accelerates patient access to critical care by jumping through all the hoops to onboard and adhere to life-saving drugs, treatments. | $6M / Seed / Sep 02, 2025 | |
Cascade Space
|
Cascade Space offers tools and ground station services for designing and analyzing communication systems in deep space missions. | $5.9M / Seed / Jul 24, 2025 | |
Terrain Bio
|
Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhancethe expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines. | $9M / Seed / Feb 12, 2025 | |
Datature
|
Datature is an AI Vision platform that simplifies computer vision development by unifying data labeling, model training, and deployment into a single workflow. By eliminating the need for fragmented tools and complex infrastructure, teams can focus on solving real-world problems. | $4M / Seed / Jul 22, 2024 | |
Maybell Quantum Industries
|
Maybell Quantum Industries is building the hardware to enable the quantum revolution. Quantum computing will help cure diseases, reverse the clock on climate change, and create millions of new jobs. | $25M / Series A / Mar 04, 2024 | |
TRLab
|
TR Lab is a blank slate platform for discovering and collecting NFT art from the artists. The company offers NFT works to collectors and art lovers. TR Lab was founded in 2021 and is headquartered in Hong Kong. | $5M / Seed / Sep 06, 2023 | |
Eureka Health
|
Eureka Health helps people with chronic conditions to mitigate their symptoms. | $7M / Seed / Jul 12, 2023 | |
|
Standard Fleet
|
Software for electric vehicle owners | $7M / Seed / Jun 14, 2023 | |
Mother Science
|
Mother Science is a revolutionary biotech beauty brand company develops next-generation skincare treatments. | $6.2M / Seed / Nov 01, 2022 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Olive Capital invest in?
Olive Capital invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Olive Capital's check size?
Olive Capital typically joins rounds of $3M–$11M at Seed and $13M–$25M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Olive Capital participates in.
How do I contact Olive Capital?
Public channels for Olive Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Olive Capital?
The team at Olive Capital includes Olivia Wang (Founder and Managing Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
